Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of IdeS in the transplantation setting. Each
patient will receive one dose of IdeS. If the crossmatch test is negative at the time of
transplantation, the patient will be transplanted with a kidney from a deceased or living
donor. The starting dose will be 0.25 mg/kg BW, given as a single intravenous infusion prior
to surgery.